Tarja Ikonen - AI Profile | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 33 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men with Metastatic Castration-Resistant Prostate Cancer

Emmanuel S. Antonarakis,Nicole Zhang,Jayati Saha,Liina Nevalaita,Tarja Ikonen, L. Jill Tsai,Chris Garratt,Karim Fizazi

JCO PRECISION ONCOLOGY (2024)

引用0浏览0WOS引用

Preliminary phase 2 results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate cancer patients

Natalie Cook,Alice Bernard-Tessier,Philippe Barthelemy,Tapio Utriainen,Guilhem Roubaud,Aude Flechon,Hans van der Voet,Gwenaelle Gravis Mescam,Raffaele Ratta, Rob Jones,Omi Parikh,Minna Tanner,Chris Garratt,Liina Nevalaita,Pasi Pohjanjousi,Tarja Ikonen,Emmanuel Antonarakis,Karim Fizazi

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2023): 87-88

引用0浏览0引用

Real-world Assessment of AR-LBD Mutations in Metastatic Castration-Resistant Prostate Cancer

Emmanuel S. Antonarakis,Nicole Zhang,Jayati Saha,Liina Nevalaita,Scott A. Shell,Chris Garratt,Tarja Ikonen,Karim Fizazi

JOURNAL OF CLINICAL ONCOLOGY (2023)

引用0浏览0引用

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

Karim Fizazi,Alice Bernard-Tessier,Guilhem Roubaud,Tapio Utriainen,Philippe Barthélémy,Aude Fléchon, Johannes van der Voet,Gwenaëlle Gravis,Raffaele Ratta,Robert Jones,Omi Parikh,Minna Tanner,Emmanuel S Antonarakis,Capucine Baldini,Niamh Peters,Chris Garratt,Tarja Ikonen,Pasi Pohjanjousi,Heikki Joensuu,Natalie Cook

NEJM evidenceno. 1 (2023): EVIDoa2300171-EVIDoa2300171

引用0浏览0WOS引用

Impact of Activating Androgen Receptor (AR) Mutations on AR Sensitivity to Alternative Ligands and Response to ODM-208, a Selective, First-in-class CYP11A1 Inhibitor, in Patients with Advanced Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Alice Bernard-Tessier,Tapio Utriainen,Natalie Cook,Philippe Barthelemy,Nada Lallous,Martin Gleave,Tarja Ikonen,Reetta Riikonen,Pasi Pohjanjousi,Chris Garratt,Karim Fizazi

Journal of clinical oncology（2022）

引用2浏览0引用

1364MO Preliminary Phase II Results of the CYPIDES Study of ODM-208 in Metastatic Castration-Resistant Prostate (mcrpc) Cancer Patients

Karim Fizazi,Alice Bernard‐Tessier, P. Barthélémy,Tapio Utriainen,Guilhem Roubaud,Aude Fléchon, J.C.M. van der Voet,Gwénaëlle Gravis,Raffaele Ratta,Robert H. Jones,Omi Parikh,Minna Tanner,Chris Garratt,Liina Nevalaita,Pasi Pohjanjousi,Tarja Ikonen,Emmanuel S. Antonarakis,Natalie Cook

Annals of oncology（2022）

引用0浏览0引用

Phase 1 Results of the ODM-208 First-in-human Phase 1-2 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (CYPIDES)

Karim Fizazi,Natalie Cook,Philippe Barthelemy,Alice Bernard-Tessier,Capucine Baldini,Niamh Peters,Pirjo Nykanen,Tarja Ikonen,Pasi Pohjanjousi,Leena Mattila,Lauri Jouhi,Annamari Vuorela,Chris Garratt,Tapio Utriainen

Journal of clinical oncologyno. 6_suppl (2022): 18-18

引用5浏览0引用

Phase I/IIa, Open-Label, Multicentre Study to Evaluate the Optimal Dosing and Safety of ODM-203 in Patients with Advanced or Metastatic Solid Tumours

Petri Bono,Christophe Massard,Katriina J. Peltola,Analia Azaro,Antoine Italiano,Rebecca S. Kristeleit,Giuseppe Curigliano,Ulrik Lassen,Hendrik-Tobias Arkenau,Pasi Hakulinen,Chris Garratt,Tarja Ikonen,Mika V. J. Mustonen,Jordi A. Rodon

ESMO Openno. 6 (2020): e001081-e001081

引用6浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn